Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells.
Kirk JS, Wang J, Long M, Rosario S, Tracz A, Ji Y, Kumar R, Liu X, Jamroze A, Singh PK, Puzanov I, Chatta G, Cheng Q, Huang J, Wrana JL, Lovell J, Yu H, Liu S, Shen MM, Liu T, Tang DG. Kirk JS, et al. Among authors: chatta g. Cell Stem Cell. 2024 Aug 1;31(8):1203-1221.e7. doi: 10.1016/j.stem.2024.05.008. Epub 2024 Jun 14. Cell Stem Cell. 2024. PMID: 38878775
Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells.
Kirk JS, Wang J, Tracz A, Long M, Rosario SR, Ji Y, Kumar R, Liu X, Singh PK, Puzanov I, Chatta G, Cheng Q, Huang J, Wrana JL, Lovell J, Yu H, Liu S, Shen MM, Liu T, Tang DG. Kirk JS, et al. Among authors: chatta g. bioRxiv [Preprint]. 2023 Mar 6:2023.03.03.530998. doi: 10.1101/2023.03.03.530998. bioRxiv. 2023. Update in: Cell Stem Cell. 2024 Aug 1;31(8):1203-1221.e7. doi: 10.1016/j.stem.2024.05.008. PMID: 36945493 Free PMC article. Updated. Preprint.
Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises.
Li WJ, Wang Y, Liu X, Wu S, Wang M, Turowski SG, Spernyak JA, Tracz A, Abdelaal AM, Sudarshan K, Puzanov I, Chatta G, Kasinski AL, Tang DG. Li WJ, et al. Among authors: chatta g. bioRxiv [Preprint]. 2024 Jan 21:2023.11.25.568612. doi: 10.1101/2023.11.25.568612. bioRxiv. 2024. Update in: Int J Mol Sci. 2024 Feb 09;25(4):2123. doi: 10.3390/ijms25042123. PMID: 38045265 Free PMC article. Updated. Preprint.
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Apolo AB, et al. Among authors: chatta g. N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2401726. Online ahead of print. N Engl J Med. 2024. PMID: 39282902
Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients.
Vaishampayan UN, Heilbrun L, Vaishampayan N, Harper FWK, Shi D, Smith D, Green K, Guru K, Li Q, Kuettel M, Chatta G, Maier J, Dickow B, Moore TF, George S. Vaishampayan UN, et al. Among authors: chatta g. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1472-1480. doi: 10.1016/j.ijrobp.2023.11.024. Epub 2023 Nov 18. Int J Radiat Oncol Biol Phys. 2024. PMID: 37981040 Clinical Trial.
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators. van der Heijden MS, et al. Among authors: chatta g. N Engl J Med. 2023 Nov 9;389(19):1778-1789. doi: 10.1056/NEJMoa2309863. Epub 2023 Oct 22. N Engl J Med. 2023. PMID: 37870949 Clinical Trial.
87 results